Stocks
Innate Immunotherapeutics LtdINNTF
HealthcareBiotechnology
A clinical-stage biopharmaceutical company developing therapies for serious diseases, including multiple sclerosis and secondary progressive MS. Its lead product candidate, MIS416, has completed Phase 2b trials, and the company has attracted attention due to early investor interest from political figures. Investors track it for its pipeline progress and potential regulatory milestones.
Congressional Interest in Innate Immunotherapeutics Ltd (INNTF)
1 member of Congress has disclosed 1 trade in Innate Immunotherapeutics Ltd (INNTF), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
1
Sells
0
Who in Congress Is Trading INNTF?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2015-01-08 | Tom Price | buy | $1K-$15K |